IN-G&H-ORTHODONTICS
G&H Orthodontics (www.ghorthodontics.com), a leading provider of clinical solutions for the orthodontic community, today announced that it is Medical Device Regulation (MDR) certified in the European Union. Fewer than 10% of all medical device companies worldwide have achieved this milestone.
This MDR certification verifies that G&H meets the most current regulatory requirements for its systems and its portfolio. All manufacturers and vendors must recertify and meet these compliance deadlines to continue distributing medical devices in the European market. 20% of manufacturers reported that they will not invest to recertify to EU MDR.
As an MDR-certified company, G&H can continue to ensure a supply of high-quality, trusted orthodontics products to doctors and their patients.
“This is the result of two-plus years of intensive work from our team,” G&H CEO John Voskuil said. “Other manufacturers may have exited the market or focused only on aligners, but we are committed to a full portfolio and uninterrupted service to our customers.”
Since September 2020, G&H has dedicated more than 30,000 hours and invested millions of dollars to achieve MDR certification. These investments further position G&H as an authority and solutions provider in the orthodontic community.
The MDR mandates will ultimately improve patient safety with more rigorous efficacy requirements for medical devices. As an example of one measure taken to satisfy increased product traceability, G&H now uses unique device identification (UDI) mechanisms.
G&H has a long history of developing brackets, wires, elastomers, aligners and attachments. With 22,000 products now MDR certified, G&H remains dedicated to providing safe, reliable devices for the EU market and world at large.
“We’ve invested in a new plant, new equipment and new processes so that we have the highest quality products,” Voskuil said. “Our top priority is making sure doctors have the products they need to deliver the best patient care.”
About G&H Orthodontics
For over 45 years, G&H Orthodontics has been the industry’s wire experts, providing a comprehensive portfolio of products. As a manufacturer, we own everything we do with a level of accountability not found elsewhere, from sourcing raw materials to final inspection. We’re committed to fostering authentic relationships and actively solving the problems of the doctors and patients we serve. To learn more, visit www.ghorthodontics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avinor Selects Thales to Deploy Norway’s Next-Generation Nationwide Unmanned Traffic Management System9.12.2024 09:00:00 CET | Press release
Thales and Avinor have partnered to implement Norway’s next-generation nationwide Unmanned Traffic Management (UTM) system, enhancing airspace management for both unmanned and manned aircraft while ensuring full compliance with European regulatory standards. Thales' Topsky - UAS, powered by AstraUTM, will provide a scalable, automated platform for real-time traffic management, compliance monitoring, and safe integration of unmanned aircraft, paving the way for efficient air mobility operations across Norway. The new UTM system supports Norway’s vision for unmanned aviation, enabling safe, scalable drone operations and laying the groundwork for future Advanced Air Mobility (AAM) solutions alongside traditional aviation. This strategic partnership with Avinor, the Norwegian air navigation service provider and airport operator, will enable the deployment of Norway’s next-generation nationwide Unmanned Traffic Management system. This collaboration represents a major step forward in Norway’
Avanza Fonder Appoints Northern Trust to Provide Integrated Trading Solutions9.12.2024 09:00:00 CET | Press release
Selected as a Provider of Trading Servicesfor Selected Index Funds Managed by Avanza Fonder Northern Trust (Nasdaq: NTRS) today announced its Integrated Trading Solutions (ITS) outsourced trading desk is supporting Avanza Fonder, a Stockholm-based fund company providing services for private clients. Founded in 2006, Avanza Fonder is a wholly owned subsidiary of Avanza Bank Holding AB (publ). The fund company manages funds in-house and in collaboration with other managers. Northern Trust will provide outsourced trading primarily for Avanza Fonder’s Global, Emerging Market, European and US equity market index funds. Gerard Walsh, global head of Client Solutions Banking & Markets, atNorthern Trust,said: “We are delighted to be working with Avanza Fonder, a leading fund manager in the Nordic region, to support them across the trading spectrum through an integrated middle-and back-office solution. Our customised services will help Avanza Fonder navigate ongoing global market challenges, all
Kapacity.io Acquired by U.S.-based EnergyHub to Accelerate Demand-Side Flexibility in Europe9.12.2024 07:30:00 CET | Press release
Acquisition will help expand electricity retailer partnerships across Europe to drive savings for customers with distributed energy resources Kapacity.io, a European leader in heat pump optimization and flexibility, has been acquired by EnergyHub, North America's largest provider of residential flexibility solutions. Backed by EnergyHub’s resources and experience, Kapacity.io will continue to focus on expanding partnerships with electricity retailers and heat pump manufacturers to unlock the benefits of residential flexibility for consumers. EnergyHub’s distributed energy resource management system (DERMS) manages more than 1.5 million distributed energy resources (DERs) across over 100 utility programs in North America. Kapacity.io helps retailers optimize the energy consumption of heat pumps on dynamic tariffs and other flexibility offerings and provides congestion management and grid balancing services to distribution system operators (DSOs) and transmission system operators (TSOs),
FPT and RWE Sign 5-Year Master Service Agreement to Drive Innovation and Sustainability9.12.2024 03:30:00 CET | Press release
FPT has signed a five-year Master Service Agreement (MSA) with RWE, further strengthening the longstanding partnership between the two companies. The agreement aims to advance technological innovation, operational excellence, and sustainable growth, supporting RWE’s ambitious initiatives in IT/OT convergence, renewable energy, and data-driven solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241208877842/en/ The signing ceremony took place in Essen, Germany, with the participation of Ms. Katja van Doren, Member of the Executive Board of RWE AG (L), Mdm. Chu Thi Thanh Ha, FPT Software Chairwoman (R), and senior leaders of both companies. (Photo: Business Wire) The signing ceremony in Essen, Germany, marks the beginning of an enhanced collaboration where FPT will provide a robust offshore utilization strategy through its Offshore Delivery Center. This will enable cost-effective, scalable solutions tailored to RWE’s evo
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update8.12.2024 18:52:00 CET | Press release
- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ - - Safety profile consistent with busulfan conditioning andautologous hematopoietic stem cell transplant -- Vertex provides update on progress in bringing CASGEVY to patients - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom